Imiquimod
Imikeraderm is used to treat actinic keratosis.
Actinic keratosis is a condition characterized by the appearance of rough patches on the skin of people who have been exposed to the sun for a long time. Some skin changes are skin-colored, while others may be grayish, pink, red, or brown. These changes can be flat and scaly or raised, rough, hard, and wart-like. Imikeraderm can only be used on flat actinic keratosis on the face and balding scalp, in patients with a normally functioning immune system, if the doctor considers that treatment with Imikeraderm cream is the most suitable for the patient.
Imikeraderm helps the body's immune system produce natural substances that help fight actinic keratosis.
Before starting treatment with Imikeraderm, discuss it with your doctor or pharmacist.
During treatment with Imikeraderm, do not use sunbeds and, if possible, avoid sunlight. When outdoors, wear protective clothing and a hat with a wide brim.
During treatment with Imikeraderm, until the skin changes have healed, the treated area may differ significantly from normal skin.
It is not recommended to use this medicine in children and adolescents.
tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take.
there are no known medicines that interact with Imikeraderm.
you must tell your doctor if you are pregnant or planning to become pregnant. Your doctor will discuss the risks and benefits of using Imikeraderm during pregnancy. Animal studies do not show a direct or indirect harmful effect on pregnancy.
do not breastfeed while using Imikeraderm, as it is not known whether imiquimod is excreted in human milk.
this medicine has no or negligible influence on the ability to drive and use machines.
methyl parahydroxybenzoate (E 218) and propyl parahydroxybenzoate (E 216) may cause allergic reactions (possible late reactions).
cetyl alcohol and stearyl alcohol may cause local skin reactions (e.g., contact dermatitis).
the medicine contains 5 mg of benzyl alcohol in each sachet. Benzyl alcohol may cause allergic reactions and mild local irritation.
butylhydroxytoluene (E 321) may cause local skin reactions (e.g., contact dermatitis) or eye and mucous membrane irritation.
it is not recommended to use this medicine in children and adolescents.
always use this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
before and after applying the cream, wash your hands thoroughly. Do not cover the treated area with bandages or other dressings after applying Imikeraderm.
each time you use the cream, use a new sachet. After using the cream from the sachet, remove the sachet with the remaining cream. Do not leave an open sachet for later use.
Instructions for use (Monday, Wednesday, and Friday)
Imikeraderm should be applied 3 times a week, for example on Monday, Wednesday, and Friday. One sachet contains enough cream to cover an area of about 25 cm². Continue treatment for 4 weeks. After the first 4 weeks of treatment, your doctor will assess the condition of your skin. If the changes have not disappeared, it may be necessary to extend the treatment by another 4 weeks.
wash off the excess with water and mild soap. After the skin reaction has subsided, you can restart the treatment.
if you accidentally swallow Imikeraderm, contact your doctor.
do not use the cream more than once a day.
like all medicines, Imikeraderm can cause side effects, although not everybody gets them.
if you experience any side effects during treatment with Imikeraderm, tell your doctor or pharmacist as soon as possible.
some patients have experienced skin discoloration at the site of application of Imikeraderm.
although these changes usually disappear over time, in some patients they may be permanent. If your skin reacts badly during treatment with Imikeraderm, stop using the cream, wash the treated area with water and mild soap, and contact your doctor or pharmacist.
some patients have experienced a decrease in blood cell count. A decrease in blood cell count may increase the risk of infection, cause more frequent bruising, or cause fatigue. If you experience such symptoms, tell your doctor.
in some patients with autoimmune disorders, their condition may worsen. If you notice any changes during treatment with Imikeraderm, tell your doctor.
rarely, serious skin reactions have been reported. If you experience skin changes or spots on the skin, initially as small red spots, and then as small dots, which may be accompanied by symptoms such as itching, fever, general malaise, joint pain, eye problems, burning, pain, or itching of the eyes, and mouth ulcers, stop using Imikeraderm and inform your doctor.
a small number of patients have experienced hair loss at the site of application or in its vicinity.
the cause of many side effects of Imikeraderm is local action on the skin. Local skin reactions may indicate that the medicine is working as intended.
very commonside effects include mild itching in the treated skin area.
commonside effects include pain, burning sensation, irritation, or redness.
apart from skin reactions, other common side effects include headache, loss of appetite, nausea, muscle and joint pain, and feeling tired.
uncommonside effects have been reported in some patients, including changes at the site of application (bleeding, inflammatory reaction, discharge, hypersensitivity, swelling, swelling of small areas of skin, tingling, flaking, scarring, ulceration, or feelings of warmth or discomfort) or inflammatory reactions of the mucous membrane lining the nose, nasal congestion, flu-like symptoms, depression, eye irritation, swelling of the eyelids, sore throat, diarrhea, actinic keratosis, redness, swelling of the face, ulcers, limb pain, fever, weakness, or chills.
Jerozolimskie Avenue 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
side effects can also be reported to the marketing authorization holder.
by reporting side effects, you can help provide more information on the safety of this medicine.
keep the medicine out of the sight and reach of children.
do not store above 25°C.
do not use this medicine after the expiry date stated on the packaging and sachet after "EXP".
the expiry date refers to the last day of the month.
do not reuse the cream from an open sachet.
medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
the active substance is:
imiquimod.
each sachet contains 250 mg of cream (100 mg of cream contains 5 mg of imiquimod).
the other ingredients are:
isostearic acid, benzyl alcohol, white petrolatum (stabilized with butylhydroxytoluene E 321), cetyl alcohol, stearyl alcohol, polysorbate 60, sorbitan stearate (type I), glycerol, methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), xanthan gum, purified water (see also section 2).
each Imikeraderm sachet contains 250 mg of cream, white to light yellow in color. Each pack contains 12 single-use sachets made of PET/LDPE/Aluminum/Surlyn.
not all pack sizes may be marketed.
SUN-FARM Sp. z o.o.
Dolna 21
05-092 Łomianki
phone: +48 22 350 66 69
mibe GmbH Arzneimittel
Münchener Straße 15
06796 Brehna
Germany
SUN-FARM Sp. z o.o.
Dolna 21
05-092 Łomianki
Germany:
Imikeraderm 50 mg/g Creme
Austria:
Imikeraderm 50 mg/g Creme
Poland:
Imikeraderm
Spain:
Imikeraderm 50 mg/g crema
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.